Suscribirse

Insulin-like growth factor binding protein-1 levels in the diagnosis of hypoglycemia caused by hyperinsulinism - 11/09/11

Doi : 10.1016/S0022-3476(97)70153-7 
Lorraine E. Levitt Katz, MDa, Marta S. Satin-Smith, MD, Paulo Collett-Solberg, MD, Paul S. Thornton, MBBCh, Lester Baker, MD, Charles A. Stanley, MD, Pinchas Cohen, MD

From the Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia.


Abstract

The diagnosis of hypoglycemia caused by hyperinsulinism may be difficult because insulin levels are not uniformly elevated at the time of hypoglycemia. Insulin-like growth factor binding protein-1 (IGFBP-1) is a 28 kd protein whose secretion is acutely inhibited by insulin. We hypothesized that serum levels of IGFBP-1 would be a useful marker of hyperinsulinism. We measured IGFBP-1 levels during the course of standardized fasting studies in hospitalized children; 36 patients became hypoglycemic during the fasting studies, and samples obtained at the point of hypoglycemia were analyzed. On the basis of the currently used diagnostic criteria, 13 children had hyperinsulinism, 16 had ketotic hypoglycemia or no disorder, 3 had hypopituitarism or isolated growth hormone deficiency, 2 had glycogen storage disease type I, and 2 had fatty acid oxidation disorders. In control subjects (children with ketotic hypoglycemia or no disorder), IGFBP-1 levels rose during fasting to a mean of 343.8 ± 71.3 ng/ml in the sample drawn at the time of hypoglycemia. Mean IGFBP-1 levels at hypoglycemia for the entire group with hyperinsulinism were 52.4 ± 11.5 ng/ml, significantly different from levels seen in control subjects (p < 0.0001). In children with moderately controlled hyperinsulinism (fasting tolerance >4 hours), mean IGFBP-1 levels at the time of hypoglycemia were 71.5 ± 16.9 ng/ml. IGFBP-1 levels in the children with poorly controlled hyperinsulinism (fasting tolerance <4 hours) failed to rise during fasting, with a mean of 30.1 ± 10.4 ng/ml in the final sample. IGFBP-1 levels were inversely correlated with serum insulin and C-peptide levels (r = –0.71 and –0.72, respectively; p < 0.0001). Patients with other endocrinologic or metabolic diseases that result in fasting hypoglycemia demonstrated a rise in IGFBP-1 levels similar to that seen in ketotic hypoglycemia. Low serum levels of IGFBP-1 at the time of hypoglycemia provide an additional marker of insulin action that might help to differentiate hyperinsulinism from other hypoglycemic disorders. (J Pediatr 1997;131:193-9)

El texto completo de este artículo está disponible en PDF.

Abbreviations : IGF, IGFBP-1


Esquema


 a Recipient of the Society for Pediatric Research Fellow’s Clinical Research Award for this presentation.
 Supported in part by U.S. Food and Drug Association grant FD-R 001181-01 (Dr. Cohen), National Institutes of Health grant RR-00240 (Drs. Baker and Stanley), an American Diabetes Association Career Development Award (Dr. Cohen), and a Lawson Wilkins Pediatric Endocrine Society Serono Fellowship (Dr. Levitt Katz).
 Reprint requests: Lorraine E. L. Katz, MD, Assistant Professor of Pediatrics, Children’s Hospital of Philadelphia, Division of Endocrinology, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104.
 0022-3476/97/$5.00 + 0 9/21/79490


© 1997  Mosby, Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 131 - N° 2

P. 193-199 - août 1997 Regresar al número
Artículo precedente Artículo precedente
  • Ehrlichiosis in children
  • Richard F. Jacobs, Gordon E. Schutze, From the Departments of Pediatrics and Pathology, University of Arkansas for Medical Sciences, Arkansas Children’s Hospital, Little Rock, Arkansas.
| Artículo siguiente Artículo siguiente
  • Effect of dietary linoleic/alpha-linolenic acid ratio on growth and visual function of term infants
  • Craig L. Jensen, Thomas C. Prager, J.Kennard Fraley, Huiming Chen, Robert E. Anderson, William C. Heird

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.